Image credit: Canva
Prostate cancer is the most common cancer and the second leading cause of cancer death among men in the United States. A clinical trial led by William Douglas Figg Sr., Pharm.D., Senior Investigator in the Genitourinary Malignancies Branch is researching a drug therapy for patients with advanced prostate cancer who have received prior abiraterone or enzalutamide and have documented evidence of progression. The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact Deneise Francis at 240-858-3974 or deneise.francis@nih.gov
Clinicaltrials.gov identifier: NCT04729114
NCI Protocol ID: 000418
Official Title: Phase 1/2a, Open-Label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
